US 11026997
Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
granted A61KA61K38/1709A61K38/1793
Quick answer
US patent 11026997 (Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61K, A61K38/1709, A61K38/1793, A61K38/2006, A61K39/395